RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.
An RNA melanoma vaccine was investigated to induce protective immunity in a mouse-melanoma model. LacZ mRNA was synthesized in vitro by pSFV3 expression vector and introduced into the spleen of mice, using HVJ-liposomes. A high level of beta-galactosidase activity was detected for 10 days in mouse spleen. The human melanoma-associated antigen gp100 mRNA was synthesized in vitro by pSFV3 vector and encapsulated in HVJ-liposomes. Immunization by direct injection of the gp100 mRNA HVJ-liposomes into mouse spleen induced both anti-gp100 Ab and CTL responses against B16 melanoma. Immunization by administration of gp100 mRNA into the spleen delayed tumor growth and significantly prolonged survival compared with control treated mice. These preclinical studies demonstrate that an RNA tumor antigen vaccine strategy has potential application for human cancer treatment and prevention.
Zhou
W Z
WZ
Division of Gene Therapy Science, Osaka University School of Medicine, Suita, Japan.
Hoon
D S
DS
Huang
S K
SK
Fujii
S
S
Hashimoto
K
K
Morishita
R
R
Kaneda
Y
Y
D000818:Animals; D019496:Cancer Vaccines / Q000494:pharmacology*; D003601:Cytotoxicity Tests, Immunologic; D018014:Gene Transfer Techniques; D006801:Humans; D007267:Injections; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000276:immunology* / Q000401:mortality; D008562:Membrane Glycoproteins / Q000235:genetics* / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009363:Neoplasm Proteins / Q000235:genetics* / Q000276:immunology; D012333:RNA, Messenger / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000276:immunology; D015996:Survival Rate; D014614:Vaccines, Synthetic / Q000494:pharmacology; D058951:gp100 Melanoma Antigen
D019496:Cancer Vaccines; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C548637:PMEL protein, human; C548642:Pmel protein, mouse; D012333:RNA, Messenger; D014614:Vaccines, Synthetic; D058951:gp100 Melanoma Antigen